תאריך רישום: March 1, 1999

מסלול הגשה: מולקולה חדשה

יצרן: ASPEN NOTRE DAME DE BONDEVILLE, FRANCE

בעל רישום: GLAXO SMITH KLINE (ISRAEL) LTD

:ATC Code

4.1 Therapeutic indications Varilrix is intended for the active immunization against varicella of the categories of persons listed below, where there is no history of varicella. - Healthy subjects, from the age of 12 months. - Patients at high risk of severe varicella, such as patients with acute leukemia or a chronic condition, those on immunosuppressive therapy or those for whom an organ transplant is being considered (see also section 4.4). - Healthy persons living in close contact with patients with varicella and high-risk patients (see also section 4.4).

תאריך רישום: August 15, 1999

מסלול הגשה: מולקולה חדשה

יצרן: DELPHARM SAINT REMY, FRANCE

בעל רישום: BIOTIS LTD

J01FA01 :ATC Code

4.1. Therapeutic indications For the treatment of bacterial infections susceptible to erythromycin and require I.V. treatment.

תאריך רישום: March 1, 1973

מסלול הגשה: מולקולה חדשה

יצרן: GSK CONSUMER HEALTHCARE SARL, SWITZERLAND

בעל רישום: HALEON CH ISRAEL LTD.

R01AA07 :ATC Code

4.1 Therapeutic indications Rapid relief of nasal congestion for up to ten hours in adults and adolescents aged 12 years and older.

תאריך רישום: November 10, 2004

מסלול הגשה: מולקולה חדשה

יצרן: CATALENT PHARMA SOLUTIONS, USA

בעל רישום: HALEON CH ISRAEL LTD.

M01AE01 :ATC Code

4.1. Therapeutic indications For the relief of mild to moderate pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Anti-inflammatory for rheumatic diseases. For the treatment of pain associated with migraine.

תאריך רישום: March 2, 2009

מסלול הגשה: מולקולה חדשה

יצרן: BAYER AG, GERMANY

בעל רישום: BAYER ISRAEL LTD

G03AA12 :ATC Code

4.1 Therapeutic indications • Oral contraception. • Treatment of moderate acne vulgaris in women who seek oral contraception. • Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who have chosen oral contraceptives as their method of birth control. The efficacy of YAZ for PMDD was not assessed beyond 3 cycles. YAZ has not been evaluated for treatment of PMS (premenstrual syndrome). The decision to prescribe YAZ should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with YAZ compares with other Combined Hormonal Contraceptives (CHCs) (see sections 4.3 and 4.4).

תאריך רישום: March 2, 2016

מסלול הגשה: מולקולה חדשה

יצרן: DELPHARM POZNAN S.A.,POLAND

בעל רישום: GLAXO SMITH KLINE (ISRAEL) LTD

N06AB05 :ATC Code

4.1 Therapeutic indications Treatment of (in adults): - Major Depressive Disorder - Obsessive Compulsive Disorder (OCD) - Panic Disorder with and without agoraphobia - Social Anxiety Disorders/Social phobia - Generalised Anxiety Disorder - Post-Traumatic Stress Disorder